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OBJECTIVE — Toassessthecost-effectivenessofintensiveversusconventionaltherapyfor8
years as applied in the Steno-2 study in patients with type 2 diabetes and microalbuminuria.
RESEARCH DESIGN AND METHODS — A Markov model was developed to incor-
porate event and risk data from Steno-2 and account Danish-speciﬁc costs to project life expect-
ancy, quality-adjusted life expectancy (QALE), and lifetime direct medical costs expressed in
year 2005 Euros. Clinical and cost outcomes were projected over patient lifetimes and dis-
counted at 3% annually. Sensitivity analyses were performed.
RESULTS — Intensive treatment was associated with increased life expectancy, QALE, and
lifetime costs compared with conventional treatment. Mean  SD undiscounted life expectancy
was18.17.9yearswithintensivetreatmentand16.27.3yearswithconventionaltreatment
(difference 1.9 years). Discounted life expectancy was 13.4  4.8 years with intensive treatment
and 12.4  4.5 years with conventional treatment. Lifetime costs (discounted) for intensive and
conventionaltreatmentwere€45,52119,697and€41,31927,500,respectively(difference
€4,202). Increased costs with intensive treatment were due to increased pharmacy and consul-
tationcosts.DiscountedQALEwas1.66quality-adjustedlife-years(QALYs)higherforintensive
(10.2  3.6 QALYs) versus conventional (8.6  2.7 QALYs) treatment, resulting in an incre-
mental cost-effectiveness ratio of €2,538 per QALY gained. This is considered a conservative
estimate because accounting prescription of generic drugs and capturing indirect costs would
further favor intensiﬁed therapy.
CONCLUSIONS — FromahealthcarepayerperspectiveinDenmark,intensivetherapywas
more cost-effective than conventional treatment. Assuming that patients in both arms were
treated in a primary care setting, intensive therapy became dominant (cost- and lifesaving).
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C
ardiovascular disease mortality is
the most common cause of death in
patients with type 2 diabetes, with
an incidence at least double that in the
generalpopulation(1).Moreover,cardio-
vascular morbidity is a major illness bur-
den in these patients and contributes
substantially to the overall costs associ-
ated with type 2 diabetes. The total direct
annualcostsofdiabetesineightEuropean
countries were estimated at €29 billion,
with an estimated yearly cost per patient
of €2,834 (2). Similarly, in the U.S., dia-
betes is reported to be associated with an-
nual direct medical expenditures of
approximately $91.8 billion, with per cap-
ita costs totaling $13,243 for individuals
with diabetes compared with $2,560 for
thosewithout(3).Cardiovasculardiseasein
patients with type 2 diabetes presents seri-
oushealthandeconomicconcernstohealth
caresystems,withhealthcarepolicymakers
having to decide how to make the most ef-
ﬁcient use of limited health care budgets.
New interventions that improve pa-
tient outcomes are generally associated
with increased costs. The American Dia-
betes Association recommends a multi-
factorial approach to the treatment of
patients with diabetes, including strict
attention to glycemic control and ag-
gressive management of cardiovascular
risk factors (4). Until the recent Steno-2
study,dataonthelong-termeffectofsuch
an approach was lacking. To determine
whether the intensive approach aimed at
treating patients with type 2 diabetes and
microalbuminuria for 7.8 years to recom-
mended targets in the Steno-2 study
would represent good value for the
money, this study aimed to assess the
cost-effectiveness of intensive versus con-
ventional therapy as applied in the
Steno-2 study from the perspective of a
national health care provider in Denmark.
RESEARCH DESIGN AND
METHODS— The Steno-2 study was
a randomized, open, parallel trial un-
dertaken by the Steno Diabetes Center in
Copenhagen, Denmark (5). At baseline,
all patients had type 2 diabetes and
microalbuminuria, a well-established in-
dependent risk factor for cardiovascular
disease (6,7). Eighty patients were ran-
domly assigned to receive conventional
treatment for multiple risk factors from
their general practitioner in accordance
with national guidelines. The remaining
80 patients were assigned to intensive
multifactorial treatment at the Steno Dia-
betes Center. The primary end point for
the macrovascular analysis following 7.8
years of intervention was a composite of
cardiovascular disease (nonfatal myo-
cardial infarction, nonfatal stroke, per-
cutaneous coronary intervention, and
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larization of the leg, lower-extremity am-
putation, and cardiovascular disease–
related death. Compared with patients in
the conventional therapy arm, patients
assigned to intensive therapy had a 53%
(95% CI 27–76) lower relative risk of car-
diovascular disease.
Model
A Markov model was developed using
TreeAgePro(TreeAgeSoftware,Williams-
town, MA) to project the long-term clini-
cal and cost outcomes associated with the
conventional and intensive treatment
armsappliedintheSteno-2study(8–10).
The model incorporated event probabili-
ties and risk data from the study (and ac-
counted Danish-speciﬁc costs) to
estimate life expectancy, quality-adjusted
life expectancy, and lifetime direct medi-
cal costs associated with the two treat-
ment arms.
A two-state Markov model (alive and
dead) with a cycle length of 1 year was
developed. The model was designed to
capture the occurrence of the following
events from the Steno-2 Study: myocar-
dial infarction, coronary artery bypass
grafting, percutaneous coronary inter-
vention,stroke(majorandminor),hospi-
talization for congestive heart failure,
revascularization of leg, revascularization
of carotid artery, lower-extremity am-
putation (toe and major amputation) due
to diabetes, end-stage renal disease, and
dialysis.
For the modeling analysis, cohort
characteristics and event rates were ap-
plied as observed in the Steno-2 study
for years 1–8 of the analysis, after which
mean event rates were carried forward
for subsequent years of simulation (see
tables in online appendices 1 and 2,
available at http://dx.doi.org/10.2337/
dc07-2452). Beyond year 8, mortality
was adjusted for age by assuming the risk
of mortality doubled every 10 years (11).
Age-dependent risk adjustments were
also applied for congestive heart failure,
cardiovascular events (myocardial infarc-
tion, percutaneous coronary interven-
tion,andcoronaryarterybypassgrafting),
stroke, and revascularization of the leg
(see online appendix 3).
Adjustment of the risk of hospitaliza-
tion for congestive heart failure according
toagewascalculatedfromariskappraisal
function derived from 486 cases of heart
failure over 38 years of follow-up (12).
Riskadjustmentforcardiovascularevents
according to patient age was performed
using the risk regression function re-
ported by the UK Prospective Diabetes
Study (UKPDS) for ﬁrst myocardial in-
farction(13)andwascalculatedforstroke
using data from the UKPDS stroke risk
engine (14). The age-related risk adjust-
ment for leg revascularization was as-
sumed to be the same as that for patients
with intermittent claudication (15).
Costs
Direct medical costs were extracted from
Danish cost databases by local experts
and expressed in year 2005 Euros (€)
(conversion rate: €1  7.45 Danish kro-
ner). Costs accounted were those related
to pharmacy; physician consultation; and
interventions associated with complica-
tions, i.e., dialysis, revascularization pro-
cedures, and amputation (Table 1). Total
costs for end-stage renal disease were ad-
justed according to the average duration
of dialysis for patients in the Steno-2
study (1.64 years) (5).
Annualtreatmentcostswereassumed
to be the sum of annual pharmacy, rem-
edy, and consultation costs. In the con-
ventional treatment arm, patients were
assigned pharmacy costs derived from
the Steno-2 study and assumed to re-
ceive all their treatment in a primary care
setting with cost of remedies and consul-
tations (physician and dietitian) in accor-
dance with previously published Danish
estimates (16). Pharmacy costs for pa-
tients in the intensive treatment arm were
also derived from the Steno-2 study, but
in the analyses patients could receive
treatment in either a primary care or spe-
cialist clinic setting. Pharmacy costs were
based on actual prices of prescribed
drugs, many of which were nongeneric.
Costs for treatment and follow-up of
microvascular complications such as ret-
inopathy and neuropathy were not in-
cludedinthisanalysis;indirectcostssuch
aslostproductionwerealsonotincluded.
In the base case analysis, patients in the
intensive treatment arm were assumed to
attend the specialist clinic at the Steno
Diabetes Center.
Quality of life
All patients were assigned a baseline
health-state utility score of 0.814, the
equivalent of the score for a patient with
uncomplicated type 2 diabetes, which
captures the reduction in quality of life
from the perfect health score of 1 (17).
Tracker variables were used in the model
to keep a record of all the events experi-
enced by simulated patients. At the be-
ginning of each cycle (or year in the
simulation), health-state utilities for each
patient were calculated by adjusting their
baseline utility scores depending on their
history of complications (see online ap-
pendix 4). Quality of life for dialysis in-
tervention was assumed to be captured in
end-stage renal disease complication and
set to zero to avoid double counting.
Discounting, time horizon, and
perspective
Clinical and cost outcomes were dis-
counted at a rate of 3% per annum in line
with current recommendations for Den-
mark (18). We modeled a lifetime hori-
zon as the base case analysis and assumed




was taken in which 1,000 patients were
run through the model 100 times using
ﬁrst-order Monte Carlo simulation to
calculate the mean and SD of costs, life
expectancy, and quality-adjusted life ex-
pectancy (QALE) (19). In the base case,
mean results of each of the 100 iterations
were used to create a scatter plot diagram
showing the differences in clinical and
cost outcomes for intensive versus con-
ventional treatment. From the scatter
plot, an acceptability curve was gen-
erated by calculating the proportion of
points below a range of willingness-to-
pay thresholds (20). This approach was
designed to capture statistical uncertainty
at the patient level with parameter level
uncertainty (e.g., effect of treatment) cap-
tured using a qualitative approach (one-
way sensitivity analysis).
Sensitivity analyses
The base case analysis was run over a 30-
year (patient lifetime) time horizon and
captured patient outcomes until year of
death. In a sensitivity analysis, the time
horizonwassetto8years,inlinewiththe
duration of the Steno-2 study. A further
sensitivity analysis was performed on the
annual discount rates for cost and clinical
outcomes, with discount rates varying
from 0 to 6% (base case 3%). In the base
case it was assumed that patients in the
intensive treatment arm would be treated
at the Steno Diabetes Center (it was as-
sumed that patients in the conventional
arm received their treatment in a primary
care setting). In a sensitivity analysis, it
wasassumedthatpatientsintheintensive
Gæde and Associates
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ment in a primary care setting. This sen-
sitivity analysis was run over both an 8-
and 30-year time horizon. A sensitivity
analysis was also performed on the clini-
cal beneﬁt observed in the Steno-2 study,
whereby patients in the intensive treat-
ment arm were assumed to receive up to
20% less clinical beneﬁt than in the base
case (i.e., risk reduction versus that in




In the base case, intensive treatment was
associated with increased life expectancy,
QALE, and lifetime costs compared with
conventional treatment. Mean  SD un-
discounted life expectancy was 18.1 
7.9 life-years with intensive treatment
and 16.2  7.3 life-years with conven-
tional treatment (difference 1.9 years).
Discountedlifeexpectancywasimproved
by 1.1 year in the intensive arm com-
pared with the conventional treatment
group (13.4  4.8 vs. 12.4  4.5 years).
Taking patients’ quality of life into ac-
count, simulated patients were pro-
jectedtolivefor10.23.6and8.62.7
quality-adjusted life years (QALYs) for
intensive and conventional treatments,
respectively (difference 1.66 QALYs).
Lifetime direct medical costs for in-
tensive and conventional treatment were
projected to be €45,520  19,697 and
€41,319  27,500, respectively (differ-
ence €4,201). A breakdown of costs re-
vealed that the increased costs associated
with intensive versus conventional treat-
ment were attributable to increased phar-
macy and consultation costs (€25,400
versus €11,289, respectively). However,
the incremental costs for intensive treat-
ment were less than those for conven-
tional treatment for all complications and
interventionsmodeledintheanalysis,de-
spite patients living longer in the inten-
sive treatment arm.
The incremental cost-effectiveness
ratio for intensive versus conventional
treatment was €2,538 per QALY gained
(Table 2). A scatter plot of mean incre-
mental costs and effectiveness for all 100
iterations was created. From this, an ac-
ceptability curve was generated showing
that, using a willingness-to-pay threshold
of €40,000 per QALY gained (21), there
was a 74% probability that the intensive
treatment would be considered cost-
effectiveversusconventionaltreatmentin
a Danish cost setting (Fig. 1).
Sensitivity analyses
The results of the base case were most
sensitive to assumptions regarding the
costs associated with physician consulta-
tion and variation in the time horizon. In
thebasecase,itwasassumedthatpatients
in the conventional treatment arm re-
ceived all of their medical care in a pri-
mary care setting, whereas patients in the
intensive treatment arm attended consul-
tations at the Steno Diabetes Center. As-
Table 1—Summary of cost inputs
Annual cost of
pharmaceuticals (€)
Conventional arm pharmacy (Steno-2) 967






Conventional arm remedies* 139
Intensive arm pharmacy (Steno-2) 1,577






Intensive arm remedies† 310
Annual costs of consultations
Conventional arm primary care consultation‡ 187
Intensive arm specialist clinic consultation 840
Base case analysis§
Intensive arm primary care consultation 187
Annual costs of complications
End-stage renal disease 65,604
CHF (hospitalization) 3,391
Myocardial infarction 3,117
Stroke (major with rehabilitation) 10,138
Stroke (minor without rehabilitation) 5,372
Annual costs of interventions
Dialysis (acute) 6,137
Revascularization of leg 9,978






2.7 measurements of blood glucose at the general practitioner (GP), 3.3 measurements of A1C, 0.2 mea-
surementsoflipidvalues,and0.5measurementsofurinaryalbumin-to-creatinineratio(16).†Intensivearm
remedies include 200 strips for home measurement of blood glucose, 4.0 measurements of blood glucose at
the GP, 4.0 measurements of glycated hemoglobin A1C, 4.0 measurements of lipid values, and 4.0 mea-
surementsofurinaryalbumin-to-creatinineratio.‡Conventionalarmconsultationsincludeanaverageof4.5
yearly consultations at the general practitioner and 0.6 consultations at a diabetes clinic including dietary
consultations by a dietitian (16). §Intensive arm consultations include 4 yearly consultations at Steno
Diabetes Center with dietary consultations by a dietitian as needed. According to Danish reimbursement
rulesthepriceforavisitataspecialistclinicis15timeshigherthanaGPconsultation(16).Allpharmacyand
consultationcostswerecalculatedbasedonresourceusedatafromtheStenoDiabetesCenterandpublished
prices. All annual costs of complications and annual costs of interventions were based on Danish National
Health Board 2005 data (26). CABG, coronary artery bypass grafting; CHF, congestive heart failure; ESRD,
end-stage renal disease; PCI, percutaneous coronary intervention.
Cost-effectiveness of intensive diabetes therapy
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arms received their care in the same pri-
marycaresetting,intensivetreatmentwas
found to be dominant (cost- and life-
saving) versus conventional treatment
(Table 3).
Shortening the time horizon to 8 years
(fromalifetimehorizoninthebasecase)led
to the incremental cost-effectiveness ratio
for intensive versus conventional treatment
increasing to €41,934 per QALY gained.
When it was assumed that consultation
costs were equal for both treatment arms
over this shorter time horizon, intensive
treatment was highly cost-effective versus
conventional treatment (€320 per QALY
gained).Sensitivityanalysesonthediscount
rates applied for cost and clinical outcomes
andreducingtheclinicaleffectivenessofin-
tensive treatment by up to 20% had little
impactontheoverallﬁndings.Theapplica-
tion of different methodologies to estimate
QALE(multiplicationonlyoradditiononly
versus multiplication and addition in the
basecase)alsohadlittleimpactontheover-
all ﬁndings.
CONCLUSIONS — The current health
economic modeling analysis based on the
8-year Steno-2 study outcome indicates
that in a Danish setting, intensive treat-
ment is likely to be associated with in-
creased life expectancy and QALE
compared with conventional treatment,
thus representing good value for the
money in patients with type 2 diabetes
and microalbuminuria. For simplicity
and transparency, the model was de-
signed only to simulate events (not states).
Therefore, state costs in the years follow-
ingclinicaleventswerenotcaptured.Fur-
thermore, the costs of medications used
in the intensive arm were those of the
original patented drugs and not the
cheaper generic versions. This very con-
servative approach was likely to underes-
timate the economic beneﬁts of intensive
versus conventional therapy. Despite
this, and given that the overall results
were most sensitive to variation in as-
sumptions regarding the costs associated
with physician consultation, intensive
treatment became dominant (cost- and
lifesaving) compared with conventional
therapy when it was assumed that pa-
tients in both treatment arms received
care in a primary care setting. Even in the
casewherepatientsintheintensivegroup
were assumed to continue the most ex-
pensive treatment in a specialist setting
and the treatment effect between the in-
tensive and conventional groups was as-
sumed to decline after the end of the 7.8-
year intervention period, this case would
still represent good value for the money
compared with other well-established
interventions.
In the base case analysis, costs and
clinical outcomes were projected over
patient lifetimes, beyond the duration of
intervention in the Steno-2 study. This is
common practice in health economic–
cost-effectiveness analyses because many
important events occur after the study
has ﬁnished. However, assumptions need
to be made on modeled data, and these
could introduce uncertainty in long-term
projections and are a limitation of such
an approach. In the present analysis, be-
yond year 8 of simulation, mean Steno-2
study event rates were applied in the
model with risk of congestive heart fail-
ure, myocardial infarction, and revascu-
larization procedures adjusted according
to patient age. These age-related risk ad-
justments were based on calculations
from the UKPDS and studies by Kannel et
al. and Murabito et al. (12–15).
The Steno-2 study was not designed
to identify those factors in the intensive
treatment arm that were most effective
in reducing the incidence of diabetes-
related complications. Had this been the
case, costs of treatment could be opti-
mized by speciﬁcally targeting those fac-
tors that contribute most to improved
patient outcomes, thereby improving the
cost-effectiveness of intensive versus con-
ventional treatment. However, in this re-
spect, previous publications from single–
risk factor intervention in patients with
newly diagnosed type 2 diabetes in the
UKPDS study have demonstrated the
cost-effectiveness of interventions against
hyperglycemia (22) and hypertension
(23), whereas the cost-effectiveness of
cholesterol-lowering therapy is well doc-
umented from other studies (24,25).
The cost-effectiveness of intensive
versus conventional multifactorial treat-
ment could also vary among patient sub-
groupsandindifferentpatientsettings.In
the Steno-2 study, all patients had type 2 Figure 1—Acceptability curve from base case analysis.
Table 2—Summary of cost and clinical outcomes in the base case analysis
Intensive Conventional Difference
Undiscounted life expectancy (years) 18.1  7.9 16.2  7.3 1.9
Life expectancy (years)* 13.4  4.8 12.4  4.5 1.1
QALE (QALYs)* 10.2  3.6 8.6  2.7 1.7
Direct medical costs (€)* 45,521  19,697 41,319  27,500 4,202
Incremental cost-effectiveness ratio €3,927 per life year gained*
€2,538 per QALY gained*
Data are means  SD unless otherwise indicated. *Values were discounted at 3% annually. All Euros are in 2005 values.
Gæde and Associates
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pendentriskfactorforcardiovasculardis-
ease), representing approximately one-
third of patients with type 2 diabetes (7).
Patients with newly diagnosed type 2 di-
abetes who have no cardiovascular risk
factors would not be expected to receive
the same clinical beneﬁt from intensiﬁed
mutifactorial treatment as patients in the
Steno-2 study, but treatment costs would
be the same. Another factor that could
affect the cost-effectiveness of the inten-
sive treatment arm is common to all in-
tensiﬁed treatments in real-life settings.
Patients recruited for the Steno-2 study
may have been more motivated, compli-
ant, and persistent with treatment than
patients in a more realistic treatment en-
vironment. Implementing the intensive
treatment arm in a real-life setting would
require training on the part of physicians
andpatientsandaﬁrmcommitmentfrom
patients to adhere to strict treatment
guidelines.
In conclusion, intensive multifacto-
rial intervention as applied in the Steno-2
study is likely to be highly cost-effective
from a third-party health care payer per-
spective in patients with type 2 diabetes
and microalbuminuria versus conven-
tional multifactorial intervention. If the
intensiﬁed intervention is implemented
in a primary care setting, cost savings
would be anticipated.
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